NEW YORK and AMSTERDAM, Aug. 14, 2025 - atai Life Sciences $(ATAI)$ announced today that they are on track to submit an End-of-Phase 2 meeting request to the U.S. Food and Drug Administration (FDA) in the third quarter of 2025. This submission is a critical step in the regulatory review of BPL-003, an intranasal psychedelic treatment for patients with treatment-resistant depression $(TRD.UK)$. The company recently reported positive topline data from the core, blinded stage of the Phase 2b clinical trial of BPL-003, demonstrating rapid, robust, and durable antidepressant effects for up to 8 weeks with a single dose. The anticipated regulatory milestone is part of atai's ongoing efforts to advance innovative mental health therapies.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.